We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+55.36%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$750M
AUM Growth
+$187M
Cap. Flow
+$114M
Cap. Flow %
15.17%
Top 10 Hldgs %
73.32%
Holding
52
New
16
Increased
12
Reduced
5
Closed
13
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$28.5M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$28M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$22M
4
ASND icon
Ascendis Pharma A/S
ASND
+$17.9M
5
KURA icon
Kura Oncology
KURA
+$16.3M

Top Sells

Rank Stock Value
1
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$29.5M
2
SGMO icon
SANGAMO THERAPEUTICS INC
SGMO
+$25.9M
3
EDIT icon
Editas Medicine
EDIT
+$12M
4
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$4.52M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$3.41M

Sector Composition

Rank Sector Weight
1 Healthcare 97.33%
2 Miscellaneous 2.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ZLAB icon
26
Zai Lab
ZLAB
$2.64B
$4.31M 0.57%
+159,535
New +$4.45M
2017 Q3
0 quarters
KIN
27
DELISTED
Kindred Biosciences, Inc.
KIN
$4.28M 0.57%
544,880
– –
2014 Q4
11 quarters
SGMO icon
28
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.34M 0.44%
222,388
-2,345,731
-91% -$25.9M
2017 Q2
1 quarter
CMTA
29
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$3.28M 0.44%
+194,166
New +$3.17M
2017 Q3
0 quarters
ADVM icon
30
DELISTED
Adverum Biotechnologies
ADVM
$2.79M 0.37%
76,295
-11,150
-13% -$309K
2016 Q3
4 quarters
CLVS
31
DELISTED
Clovis Oncology, Inc.
CLVS
$2.12M 0.28%
25,765
+15,765
+158% +$1.25M
2017 Q2
1 quarter
XNCR icon
32
Xencor
XNCR
$1.79B
$2.06M 0.28%
+90,114
New +$2M
2017 Q3
0 quarters
SGEN
33
DELISTED
Seagen Inc. Common Stock
SGEN
$1.63M 0.22%
30,000
+15,000
+100% +$768K
2017 Q2
1 quarter
ACRS icon
34
Aclaris Therapeutics
ACRS
$512M
$1.55M 0.21%
60,000
-125,472
-68% -$3.36M
2016 Q4
3 quarters
SYRS icon
35
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.53M 0.2%
+10,400
New +$1.96M
2017 Q3
0 quarters
BMY icon
36
Bristol-Myers Squibb
BMY
$124B
$1.09M 0.14%
17,060
– –
2016 Q4
3 quarters
ONC icon
37
BeOne Medicines Ltd
ONC
$42.4B
$1.01M 0.13%
+9,800
New +$730K
2017 Q3
0 quarters
DCPH icon
38
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$855K 0.11%
+45,000
New +$824K
2017 Q3
0 quarters
FSTX
39
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$269K 0.04%
+4,000
New +$229K
2017 Q3
0 quarters
AGIO icon
40
Agios Pharmaceuticals
AGIO
$1.93B
– –
-23,300
Closed -$1.2M –
ALNY icon
41
Alnylam Pharmaceuticals
ALNY
$31.3B
– –
-10,425
Closed -$831K –
EDIT icon
42
CALL
Editas Medicine
EDIT
$372M
– –
-255,000
Closed -$4.32M –
EDIT icon
43
Editas Medicine
EDIT
$372M
– –
-717,107
Closed -$12M –
GILD icon
44
CALL
Gilead Sciences
GILD
$196B
– –
-500,000
Closed -$38M –
NERV icon
45
Minerva Neurosciences
NERV
$114M
– –
-27,975
Closed -$1.98M –
CCXI icon
46
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-118,000
Closed -$1.1M –
ALXN
47
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-569,500
Closed -$78.2M –
NBRV
48
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-1,059
Closed -$2.77M –
TTPH
49
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-31,670
Closed -$4.52M –
ACHN
50
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-742,835
Closed -$3.41M –
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2017 Portfolio in Review

As of Q3 2017, EcoR1 Capital held 52 positions worth $750M, up 33% from $563M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

EcoR1 Capital deployed $114M of net new capital in Q3 2017, opening 16 new positions and adding to 12 existing holdings. Its largest new stake was Immunomedics Inc: 2,860,019 shares worth $40M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 77% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $29.5M trimmed.

  • EcoR1 Capital's largest Q3 2017 buy was Immunomedics Inc: 2,860,019 shares worth $40M.
  • EcoR1 Capital added most to Ironwood Pharmaceuticals in Q3 2017, an estimated $28M increase.
  • EcoR1 Capital's biggest Q3 2017 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $29.5M.
  • EcoR1 Capital fully exited Editas Medicine in Q3 2017, selling an estimated $12M.
  • EcoR1 Capital's ten largest holdings make up 73% of its $750M portfolio in Q3 2017.
  • EcoR1 Capital opened 16 new positions and closed 13 in Q3 2017.
  • EcoR1 Capital's portfolio value rose 33% quarter-over-quarter to $750M.

Based on EcoR1 Capital's 13F filing for Q3 2017, filed 14 Nov 2017.